2021
Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement
Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, Rathmell WK, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer 2021, 127: 3957-3966. PMID: 34343338, PMCID: PMC8711633, DOI: 10.1002/cncr.33679.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaGenetic risk assessmentHereditary renal cell carcinomaCell carcinomaConsensus statementMedical oncologistsMultidisciplinary panelPatient advocatesConsensus questionsClinical consensus statementHereditary kidney cancerMultigene panel testingClinical geneticistsFamily history criteriaPaucity of guidelinesUniform consensusStrong hereditary componentCurrent opinionGenetic counselorsMultifocal diseaseConsensus panelSpecific histologyKidney cancerRisk assessmentPanel testing
2020
Longitudinal follow-up after telephone disclosure in the randomized COGENT study
Kilbride M, Egleston B, Hall M, Patrick-Miller L, Daly M, Ganschow P, Grana G, Olopade O, Fetzer D, Brandt A, Chambers R, Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao X, Domchek S, Bradbury A. Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics In Medicine 2020, 22: 1401-1406. PMID: 32376981, PMCID: PMC7396300, DOI: 10.1038/s41436-020-0808-3.Peer-Reviewed Original ResearchConceptsDisclosure of genetic test resultsGenetic test resultsMedical follow-upEra of multigene panel testingGermline cancer genetic testingCancer genetic testingIn-person disclosureMultigene panel testingMedical management recommendationsFollow-upFollow-up appointmentsTelephone disclosureGenetic counselorsLongitudinal follow-upIn-personLongitudinal riskGenetic testingPanel testingParticipantsGenetic resultsBehavioral outcomesAssociated with sitesManagement recommendationsTD armIPD
2018
Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results
Bradbury A, Patrick-Miller L, Egleston B, Hall M, Domchek S, Daly M, Ganschow P, Grana G, Olopade O, Fetzer D, Brandt A, Chambers R, Clark D, Forman A, Gaber R, Gulden C, Horte J, Long J, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer J, Yao X. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal Of The National Cancer Institute 2018, 110: 985-993. PMID: 29490071, PMCID: PMC6136932, DOI: 10.1093/jnci/djy015.Peer-Reviewed Original ResearchConceptsIn-person disclosureMultigene panel testingGenetic test resultsTelephone disclosureIn-personPretest counselingSurgery intentionsEra of multigene panel testingCancer-specific distressCancer genetic testingGenetic testingGermline genetic testingState anxietyMultiple imputation analysisGeneralized anxietyPanel testingSubgroup analysisStatistically significant differenceSecondary subgroup analysisUsual careGenetic counselorsImputation analysisSecondary analysisSecondary outcomesConfidence intervals